USA - engelsk - NLM (National Library of Medicine)

mylan institutional llc - dimethyl sulfoxide (unii: yow8v9698h) (dimethyl sulfoxide - unii:yow8v9698h) - dimethyl sulfoxide 0.54 g in 1 ml - rimso-50® (dimethyl sulfoxide) is indicated for the symptomatic relief of patients with interstitial cystitis. rimso-50® has not been approved as being safe and effective for any other indication. there is no clinical evidence of effectiveness of dimethyl sulfoxide in the treatment of bacterial infections of the urinary tract. none known. none known.

USA - engelsk - NLM (National Library of Medicine)

mylan institutional llc - thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin 5'-phosphate sodium (unii: 20rd1dzh99) (flavin mononucleotide - unii:7n464ure7e), dexpanthenol (unii: 1o6c93ri7z) (dexpanthenol - unii:1o6c93ri7z), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z) - thiamine 100 mg in 1 ml - in disorders requiring parenteral administration of vitamins, i.e. pre- and post-operative treatment, when requirements are increased as in fever, severe burns, increased metabolism, pregnancy, gastrointestinal disorders interfering with intake or absorption of vitamins, prolonged or wasting diseases, alcoholism and where other deficiencies exist. sensitivity to the ingredients listed.

USA - engelsk - NLM (National Library of Medicine)

mylan institutional llc - levoleucovorin calcium pentahydrate (unii: wa16a5y52x) (levoleucovorin - unii:990s25980y) - levoleucovorin 10 mg in 1 ml - levoleucovorin injection is contraindicated for patients who have had previous allergic reactions attributed to folic acid or folinic acid. animal reproduction studies have not been conducted with levoleucovorin. it is not known whether levoleucovorin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. levoleucovorin should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from levoleucovorin, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. [see clinical studies (14).] clinical studies of levoleucovorin in the treatment of osteosarcoma did not include subjects aged 65 and over to determine whether they respond differently from younger subjects. in the ncctg clinical trial of levoleucovo

USA - engelsk - NLM (National Library of Medicine)

mylan institutional llc - diphenhydramine hydrochloride (unii: tc2d6jad40) (diphenhydramine - unii:8gts82s83m) - diphenhydramine hydrochloride 50 mg in 1 ml - diphenhydramine hydrochloride injection, is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical. for amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. for active treatment of motion sickness. for use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combinations with centrally acting anticholinergic agents. this drug should not be used in neonates or premature infants. because of the higher risk of antihistamines for infants generally, and for neonat

USA - engelsk - NLM (National Library of Medicine)

mylan institutional llc - thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j) - thiamine hydrochloride 100 mg in 1 ml - thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in wernicke’s encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. it is also indicated when giving iv dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be g

USA - engelsk - NLM (National Library of Medicine)

mylan institutional llc - hydralazine hydrochloride (unii: fd171b778y) (hydralazine - unii:26nak24ls8) - hydralazine hydrochloride 20 mg in 1 ml - severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure. hypersensitivity to hydralazine; coronary artery disease; mitral valvular rheumatic heart disease.

USA - engelsk - NLM (National Library of Medicine)

mylan institutional llc - magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838) - magnesium chloride 200 mg in 1 ml - as an electrolyte replenisher in magnesium deficiencies. magnesium chloride injection should not be administered if there is renal impairment, marked myocardial disease or to comatose patients.

USA - engelsk - NLM (National Library of Medicine)

mylan institutional llc - methocarbamol (unii: 125od7737x) (methocarbamol - unii:125od7737x) - methocarbamol 100 mg in 1 ml - the injectable form of methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. the mode of action of this drug has not been clearly identified, but may be related to its sedative properties. methocarbamol does not directly relax tense skeletal muscles in man. methocarbamol injection should not be administered to patients with known or suspected renal pathology. this caution is necessary because of the presence of polyethylene glycol 300 in the vehicle. a much larger amount of polyethylene glycol 300 than is present in recommended doses of methocarbamol injection is known to have increased preexisting acidosis and urea retention in patients with renal impairment. although the amount present in this preparation is well within the limits of safety, caution dictates this contraindication. methocarbamol injection is contraindicated in patients hypersensitive to methocarbamol or to any of the injec

USA - engelsk - NLM (National Library of Medicine)

mylan institutional llc - hydroxyprogesterone caproate (unii: 276f2o42f5) (hydroxyprogesterone - unii:21807m87j2) - hydroxyprogesterone caproate 250 mg in 1 ml - hydroxyprogesterone caproate injection, usp is indicated in non-pregnant women: for the treatment of advanced adenocarcinoma of the uterine corpus (stage iii or iv); in the management of amenorrhea (primary and secondary) and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer; as a test for endogenous estrogen production and for the production of secretory endometrium and desquamation. hydroxyprogesterone caproate is contraindicated in patients with known or suspected carcinoma of the breast, other hormone-sensitive cancer, or history of these conditions; undiagnosed abnormal vaginal bleeding; liver dysfunction or disease; missed abortion, and in those with a history of hypersensitivity to the drug. hydroxyprogesterone caproate is also contraindicated as a diagnostic test for pregnancy and in patients with current or history of thrombotic or thromboembolic disorders.

USA - engelsk - NLM (National Library of Medicine)

mylan institutional llc - chlorothiazide sodium (unii: sn86fg7n2k) (chlorothiazide - unii:77w477j15h) - chlorothiazide sodium for injection, usp is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. chlorothiazide sodium for injection, usp has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (see precautions, pregnancy). dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus,